Form 4: United Therapeutics CEO Sells Shares Under 10b5-1 Plan

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed pre-arranged stock option exercises and subsequent sales of common stock in late September 2025 under a 10b5-1 trading plan.

Summary

• Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp (UTHR), engaged in transactions involving company common stock on September 23 and September 24, 2025.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which was entered into on May 2, 2025.
• The 10b5-1 plan involves the exercise and sale of a tranche of 294,000 stock options that expire on March 15, 2026, and will continue until either these options are exhausted or December 31, 2025, whichever occurs first.
• On September 23, 2025, 4,000 shares were acquired through stock option exercise at a price of $120.26 per share.
• On September 23, 2025, a total of 4,000 shares were sold at weighted average prices of $416.51 (2,000 shares) and $419.7863 (2,000 shares).
• On September 24, 2025, an additional 4,000 shares were acquired through stock option exercise at a price of $120.26 per share.
• On September 24, 2025, a total of 4,000 shares were sold at weighted average prices of $433.7678 (3,316 shares) and $435.84 (684 shares).
• Following these reported transactions, direct beneficial ownership of common stock is 130 shares.
• Indirect beneficial ownership includes 166 shares held by a spouse and 644,193 shares held across various family trusts.

Sentiment

Score: 5

Explanation: The transactions are routine insider sales under a pre-arranged 10b5-1 plan, which is generally considered neutral. While it represents a reduction in direct insider ownership, the pre-planned nature mitigates any immediate negative sentiment typically associated with insider selling.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, indicating planned diversification or liquidity rather than a reaction to new, undisclosed negative information.
• The sale prices for the common stock were significantly higher than the exercise price of the options, indicating a substantial gain for the reporting person.

Negatives

• Martine A. Rothblatt, Chairperson & CEO, reduced direct beneficial ownership of common stock through these sales.

Risks

• Potential for negative market perception due to insider selling, even if pre-planned, which could lead to short-term stock price volatility.

Future Outlook

The 10b5-1 trading plan, entered into on May 2, 2025, is scheduled to continue until either a tranche of 294,000 stock options expiring March 15, 2026, is exhausted, or December 31, 2025, whichever comes first.

Management Comments

• The exercise and sale of stock options was pursuant to a pre-arranged 10b5-1 trading plan entered into by the reporting person on May 2, 2025.

Industry Context

Insider trading plans, such as 10b5-1 plans, are common mechanisms for executives in publicly traded companies to manage their equity holdings while adhering to insider trading regulations. These plans allow executives to pre-schedule sales or purchases of company stock at a time when they are not in possession of material non-public information, thereby providing an affirmative defense against insider trading allegations.

Comparison to Industry Standards

• NA

Related Party Transactions

• Shares are held in various family trusts where the Reporting Person, spouse, and/or immediate family members are beneficiaries or trustees, indicating related party ownership.

Stakeholder Impact

• Shareholders: May perceive a slight negative signal from insider selling, though this is largely mitigated by the pre-arranged nature of the 10b5-1 plan. The transactions represent a reduction in direct insider ownership.
• Management: The transactions provide liquidity and diversification for the CEO's personal holdings, which is a common practice for executives.

Next Steps

• Continuation of the 10b5-1 trading plan until December 31, 2025, or until the specified tranche of stock options is exhausted.

Key Dates

Recommendation

The filing details routine insider stock option exercises and sales executed under a pre-arranged 10b5-1 trading plan. These transactions are generally not indicative of new material information about the company's performance or outlook. Therefore, the filing itself does not provide a basis for a change in investment recommendation, and a 'hold' stance is maintained, pending further fundamental analysis of the company's operations and financial results.

Keywords

United Therapeutics, UTHR, Form 4, insider trading, stock options, 10b5-1 plan, executive compensation, share sale